Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512311 | 0.92 | DRD2 (0.59) | DRD2MCHR1 | |
| SCHEMBL5508393 | 0.91 | DRD2 (0.58) | DRD2MCHR1 | |
| SCHEMBL5519535 | 0.91 | DRD2 (0.57) | DRD2MCHR1 | |
| SCHEMBL5507896 | 0.90 | MCHR1 (0.58) | DRD2MCHR1 | |
| SCHEMBL5515369 | 0.89 | DRD2 (0.55) | DRD2MCHR1 | |
| SCHEMBL5888380 | 0.88 | DRD2 (0.55) | DRD2MCHR1 | |
| SCHEMBL5522194 | 0.87 | MCHR1 (0.54) | DRD2MCHR1 | |
| SCHEMBL5515339 | 0.87 | DRD2 (0.51) | DRD2MCHR1 | |
| SCHEMBL5507311 | 0.86 | DRD2 (0.49) | DRD2 | |
| SCHEMBL14619969 | 0.85 | DRD2 (0.61) | DRD2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590326-A4 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | LUNDBECK & CO AS H (DK) | 2008-04-30 | — | — | EP | disclosed |
| US-7199135-B2 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2007-04-03 | — | — | US | disclosed |
| US-7199135-B2 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2007-04-03 | — | — | US | disclosed |
| US-7199135-B2 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2007-04-03 | — | — | US | disclosed |
| US-20060217418-A1 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2006-09-28 | — | — | US | disclosed |
| US-7105544-B2 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060084649-A9 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2006-04-20 | — | — | US | disclosed |
| US-20060041139-A9 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. LUNDBECK A/S (DK) | 2006-02-23 | — | — | US | disclosed |
| EP-1590326-A2 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. Lundbeck A/S (DK) | 2005-11-02 | — | — | EP | disclosed |
| US-20040186103-A1 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-09-23 | — | — | US | disclosed |
| WO-2004064764-A2 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. LUNDBECK A/S (DK) | 2004-08-05 | — | — | WO | disclosed |
| US-20040073036-A1 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073036-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | DRD2 74/4885MCHR1 1/4885 |
| US-20060084649-A9 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | DRD2 74/4885MCHR1 1/4885 |
| US-20060041139-A9 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | MCHR1, MCHR2, MC1R | DRD2 74/4885MCHR1 1/4885 |
| US-20060217418-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | DRD2 74/4885MCHR1 1/4885 |
| US-20040186103-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | DRD2 74/4885MCHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.